국가: 캐나다
언어: 영어
출처: Health Canada
CANDESARTAN CILEXETIL
ACTAVIS PHARMA COMPANY
C09CA06
CANDESARTAN
8MG
TABLET
CANDESARTAN CILEXETIL 8MG
ORAL
30/100/500
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0135220002; AHFS:
CANCELLED POST MARKET
2019-08-13
_ _ _ACT CANDESARTAN Product Monograph _ _ _ _ _ _ _ _ _ _ _ _ Page 1 of 35 _ _ _ _ _ _ _ _ _ _ _ PRODUCT MONOGRAPH Pr ACT CANDESARTAN Candesartan Cilexetil Tablets 4 mg, 8 mg, 16 mg and 32 mg Angiotensin II AT 1 Receptor Blocker Actavis Pharma Company 6733 Mississauga Road, Suite 400 Mississauga, Ontario L5N 6J5 Date of Revision: May 3, 2016 Submission Control No: 194118 _ _ _ACT CANDESARTAN Product Monograph _ _ _ _ _ _ _ _ _ _ _ _ Page 2 of 35 _ _ _ _ _ _ _ _ _ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 8 DRUG INTERACTIONS ................................................................................................. 14 DOSAGE AND ADMINISTRATION ............................................................................. 16 OVERDOSAGE ............................................................................................................... 18 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 19 STORAGE AND STABILITY ......................................................................................... 21 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 22 PART II: SCIENTIFIC INFORMATION ............................................................................... 23 PHARMACEUTICAL INFORMATION ......................................................................... 23 CLINICAL TRIALS ............ 전체 문서 읽기